Hard to Treat Diseases Inc. manufactures, supplies, and exports biopharmaceuticals and vaccines in China and internationally. The company offers biologicals, including reteplase (rPA), mycobacterium vaccae, acutobin urinary kallidinogenase, ulinastatin, and cerebroprotein hydrolysate for injection; chemicals, such as cobratide injection, entecavir capsule, HES, dasatinib tablets, thymosin a1 for injection, imipenem and cilastatin sodium for injection, and meropenem for injection; and vaccines, which include rabies vaccine, ACYW135 meningococcal vaccine, influenza vaccine, Hepatitis A, and varicella vaccine. It markets its products through a sales network that focuses on South Asia, South-east Asia, Central and South America, and the Middle East. Hard to Treat Diseases Inc. was founded in 2009 and is based in Shenzhen, China.
hard to treat diseases inc
(HTDS:OTC Markets Group Inc - No Information)
Room EF, 12F
Phone: 86 755 8272 0498
Fax: 86 755 8272 0321www.mellowhope.com
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for HTDS.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact HARD TO TREAT DISEASES INC, please visit www.mellowhope.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.